Search
Oxybuprocaine
go.drugbank.com/drugs/DB00892ApprovedInvestigationalOxybuprocaine (also known as Benoxinate) is a local anesthetic, which is used especially in ophthalmology and otolaryngology.
Mixtures: AMIGDAL-B®, BUCALIV® TABLETA MASTICABLESynonyms: 4-Amino-3-butoxy-2-(diethylamino)ethyl ester benzoic acid, 4-Amino-3-butoxy-benzoic acid 2-diethylamino-ethyl esterBenznidazole
go.drugbank.com/drugs/DB11989ApprovedInvestigationalBenznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: ABALEA ®100 MGButamirate
go.drugbank.com/drugs/DB13731InvestigationalProducts: CODACTIV 7,5 MG/5 ML SURUP, 100 ML, TAMIRAL 7,5 MG / 5 ML SURUP 100 MLFlunarizine
go.drugbank.com/drugs/DB04841ApprovedInvestigationalFlunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. … It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingSynonyms: 1-[bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenylprop-2-en-1-yl]piperazineIcatibant
go.drugbank.com/drugs/DB06196ApprovedInvestigational[A4017,A263046] Icatibant was approved by the FDA on August 25, 2011, and by the EMA in 2008 as a treatment for hereditary angioedema. … Icatibant is a synthetic decapeptide with 5 nonproteinogenic amino acid antagonist targeting the B<sub>2</sub> receptors with a similar affinity to bradykinin.
Products: İKTU 30 MG/3 ML ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET, FIRAZYR 30 MG/3 ML SC ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETCeritinib
go.drugbank.com/drugs/DB09063ApprovedInvestigationalAbout 4% of patients with NSCLC have a chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-associated protein-like 4) and ALK (anaplastic lymphoma kinase), which … Following treatment with crizotinib (a first-generation ALK inhibitor), most tumours develop drug resistance due to mutations in key "gatekeeper" residues of the enzyme.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamideRiluzole
go.drugbank.com/drugs/DB00740ApprovedInvestigationalA glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. … Riluzole is marketed as Rilutek by Sanofi.
Categories: Compounds used in a research, industrial, or household setting, Cytochrome P-450 SubstratesInternational brands: Xie Yi LiTetryzoline
go.drugbank.com/drugs/DB06764Approved[A231769] Available since the 1950s, tetryzoline is a selective α<sub>1</sub>-receptor agonist [A231774] that is used as an ocular and nasal decongestant. … Tetryzoline, also known as tetrahydrozoline, is a derivative of imidazoline with central and peripheral alpha (α)-adrenergic properties.
Mixtures: ISCHEMOL A, ISCHEMOL ACategories: Compounds used in a research, industrial, or household setting, Adrenergic alpha-1 Receptor AgonistsPrazosin
go.drugbank.com/drugs/DB00457ApprovedInvestigationalPrazosin is a drug used to treat hypertension. Prazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988. … [L5828] It belongs to the class of drugs known as alpha-1 antagonists.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: 2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline, 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazineMetyrapone
go.drugbank.com/drugs/DB01011ApprovedInvestigationalAn inhibitor of the enzyme steroid 11-beta-monooxygenase. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of cushing syndrome.
Categories: Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP3A InducersProducts: Metycor 250 mg Weichkapseln